Cambridge Healthtech Institute’s Third Annual 

Predictive Preclinical Models in Oncology 

Mastering Translational Oncology with Predictive Models and Novel In-Silico Approaches

March 7-9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference


Despite tremendous progress in our understanding of cancer biology, the majority of novel anticancer therapies fail in clinical trials, which indicates failure of conventional translational approaches. A major challenge in the development of novel anticancer agents is the design and interpretation of first-in-man trials. The key study design elements such as schedule, escalation strategy, targeted patient population, etc. rely heavily on preclinical (usually in vivo) data. This situation brings into question the predictability of preclinical tumor models as well as the method to analyze and translate the results of preclinical studies. In that regard, better in vivo models, coupled with careful translational PK/PD modeling hold the potential to significantly increase the value of preclinical results. Better predictive modeling would hopefully permit more effective evaluation of novel cancer therapeutics, (for example, cancer immunotherapeutics), as well as the more rational design of potent anticancer drug combinations. Cambridge Healthtech Institute’s Fourth Annual Predictive Pre-Clinical Models in Oncology is designed to highlight cutting edge advances in in vivo, in vitro and in silico modeling and to facilitate a discussion about effective translational approaches in cancer research.

Who should attend: Cancer researchers working at pharmaceutical and biotech companies as well as academic centers should attend this conference

Topics will include, but are not limited to:

  • Modeling inter-patient response heterogeneity using PDX models
  • PDX models to inform clinical trials
  • Translational PK/PD modeling for bridging to first-in-human trial design
  • Predictive biomarker identification in murine models
  • Genomic analyses in support of preclinical cancer research
  • Preclinical studies for combination cancer therapy: designing effective combinations and assessing synergy toxicity
  • Modeling primary, resistant and metastatic tumors
  • Mouse trials: following human clinical trial approaches
  • Validation of animal models and assessment of their predictability
  • Immunocompetent models for preclinical assessment of cancer immunotherapy
  • Syngeneic models for immunotherapy assessment
  • Exploring combination of targeted therapy and immunotherapy
  • Novel 3D tissue models and their applications

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is August 28, 2015.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Senior Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5406

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483

Joseph Vacca (Companies L-Z)
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431

Premier Sponsors:  



Jackson Laboratory - small logo 


 Precision for Medicine 


Silicon Biosystems

Thomson Reuters-Large